Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) traded down 3.9% during trading on Friday . The stock traded as low as $10.46 and last traded at $10.36. 8,771 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 245,725 shares. The stock had previously closed at $10.77.
Wall Street Analyst Weigh In
Several research analysts have issued reports on the stock. TD Cowen started coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set a "buy" rating on the stock. William Blair assumed coverage on Upstream Bio in a report on Tuesday, November 5th. They set an "outperform" rating on the stock. JPMorgan Chase & Co. started coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an "overweight" rating and a $38.00 price objective for the company. Finally, Piper Sandler began coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $75.00 target price on the stock.
Read Our Latest Analysis on UPB
Upstream Bio Trading Down 3.5 %
The firm's 50-day moving average is $17.55.
Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($6.38). The business had revenue of $0.61 million during the quarter, compared to analysts' expectations of $0.83 million. Research analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.
Institutional Investors Weigh In On Upstream Bio
A hedge fund recently bought a new stake in Upstream Bio stock. Moody Aldrich Partners LLC acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 74,773 shares of the company's stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned 0.14% of Upstream Bio at the end of the most recent reporting period.
Upstream Bio Company Profile
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
